RESUMO
Objective: To assess the clinicopathological and radiological imaging characteristics of patients with primary breast lymphoma. Methods: The clinical and imaging data of patients diagnosed with primary breast lymphoma in West China Hospital of Sichuan University from January 2011 to October 2017 were retrospectively analyzed. The imaging modalities were assessed by mammography, B-ultrasound and PET-CT. The clinicopathological features and radiological imaging characteristics of breast lesions were summarized and analyzed. Results: The fifty-three patients with 70 intramammary lesions were contained in this research. Most patients were females (n = 52, 98.11%), and the median age was 48 years old. Primary breast lymphoma were divided into non-Hodgkin lymphoma (NHL) (n = 51, 96.23%) and Hodgkin lymphoma (HL)(n = 2, 3.77%). Among the patients with NHL, there were 33 cases (62.26%) of diffuse large B-cell lymphoma, 5 cases (9.43%) of B-cell lymphoma, 5 cases (9.43%) of extranodal natural killer (NK)/T-cell lymphoma (nasal type), 2 cases (3.77%) of mantle cell lymphoma, 2 cases (3.77%) of follicular cell lymphoma, 2 cases (3.77%) of T-lymphoblastic lymphoma, 1 case (1.89%) of anaplastic large cell lymphoma, and 1 case (1.89%) of plasmacytic lymphoma. There was no statistical difference (all P > 0.05) in the maximum transverse diameter and the number of lesions among the pathological subtypes. The mammography showed that the most common manifestations were high density irregular lumps with indistinct edges. B-ultrasound showed that the lessions were presented as the irregular masses with hypoechoic pattern and circumscribed margins. PET-CT showed the majority of lesions were solitary or multiple intramammary masses with irregular shape and circumscribed margins. The percentages of lesions classified by mammography, PET-CT and B-ultrasound as breast imaging-reporting and data systems (BI-RADS) 4-5 were 100%, 94.50% and 86.10%, respectively. Conclusion: The imaging manifestations of primary breast lymphoma are varied and unique. PET-CT has good diagnostic value for the BI-RADS classification of primary breast lymphoma.
RESUMO
BACKGROUND@#The aim of this study is to systematically evaluate the efficacy and adverse effects of Lobaplatin and Cisplatin in the treatment of malignant pleural effusion.@*METHODS@#The databases of Medline (PubMed), Embase, Web of Science, Cochrane, Wanfang, CNKI and VIP were retrieved so as to search the studies about the randomized controlled clinical trials (RCT) that compared the Lobaplatin and Cisplatin for malignant pleural effusion. The main outcome indicators include objective response rate, complete response, partial response, nephrotoxicity, chest pain, gastrointestinal reaction, myelosuppression, fever response and hepatotoxicity. Relative risk was used as the effect size, which was expressed as 95% confidence interval. The meta-analysis was performed using Stata 14.0 statistical software.@*RESULTS@#A total of 12 RCTs and 720 MPE patients were included. The results showed that the ORR (RR=1.27, 95%CI: 1.15-1.40, P<0.001), CR (RR=1.39, 95%CI: 1.09-1.78, P=0.007), PR (RR=1.21, 95%CI: 1.02-1.42, P=0.026) in LBP thoracic perfusion chemotherapy were significantly higher than those in DDP thoracic perfusion chemotherapy. The incidence of nephrotoxicity (RR=0.31, 95%CI: 0.13-0.71, P=0.005) and gastrointestinal reactions (RR=0.44, 95%CI: 0.31-0.62, P<0.001) in the LBP group were significantly lower than those in DDP group.@*CONCLUSIONS@#Compared with DDP pleural perfusion chemotherapy, the ORR, CR and PR of LBP pleural perfusion chemotherapy for MPE are significantly better than DDP, and its nephrotoxicity and gastrointestinal reactions are remarkably lower than DDP.